{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Tafasitamab, Lenalidomide and Venetoclax Combination Therapy for Relapsed or Refractory Mantle Cell Lymphoma (V-MIND): A Phase II Study with Safety Lead-in","item":"https:\/\/www.regionalcancercare.org\/trials\/tafasitamab-lenalidomide-and-venetoclax-combination-therapy-for-relapsed-or-refractory-mantle-cell-lymphoma-v-mind-a-phase-ii-study-with-safety-lead-in\/#breadcrumbitem"}]}